| HOME >> BIOLOGY >> TECHNOLOGY |
DIVIDENDS (424,815) -
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS $(2,414,093) $(5,554,976)
NET LOSS PER COMMON SHARE (BASIC) $ (0.02) $ (0.05)
NET LOSS PER COMMON SHARE (DILUTED) $ (0.02) $ (0.05)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING,
BASIC & DILUTED 117,773,569 108,526,680
CEL-SCI CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Nine Months Ended
June 30,
2008 2007
REVENUE:
Grant revenue $ 3,535 $ 31,779
Rent income 1,530 18,629
Other income - 1,556
Total Revenue 5,065 51,964
EXPENSES:
Research and development, excluding
depreciation of $101,005 and $62,364
included below 3,041,212 1,817,891
Depreciation and amortization 161,211 129,247
General and administrative 3,931,857 5,473,605
Total Expenses 7,134,280 7,420,743
LOSS FROM OPERATIONS (7,129,215) (7,368,779)
GAIN (LOSS) ON DERIVATIVE INSTRUMENTS 35,157 (818,580)
INTEREST INCOME 430,320 362,777
INTEREST EXPENSE (378,569) (1,566,638)
NET LOSS BEFORE INCOME TAXES
'/>"/>
| SOURCE CEL-SCI CORPORATION Copyright©2008 PR Newswire. All rights reserved |